View Item 

Show simple item record

Biopharmaceutical optimization in neglected diseases for paediatric patients by applying the provisional paediatric biopharmaceutical classification system
dc.contributor.authorMoral Sanchez, Jose Manuel
dc.contributor.authorGonzalez‐alvarez, Isabel
dc.contributor.authorCerda‐revert, Aaron
dc.contributor.authorGonzalez‐alvarez, Marta
dc.contributor.authorNavarro‐ruiz, Andres
dc.contributor.authorAmidon, Gordon L.
dc.contributor.authorBermejo, Marival
dc.date.accessioned2018-11-20T15:31:15Z
dc.date.available2019-12-02T14:55:08Zen
dc.date.issued2018-10
dc.identifier.citationMoral Sanchez, Jose Manuel; Gonzalez‐alvarez, Isabel ; Cerda‐revert, Aaron ; Gonzalez‐alvarez, Marta ; Navarro‐ruiz, Andres ; Amidon, Gordon L.; Bermejo, Marival (2018). "Biopharmaceutical optimization in neglected diseases for paediatric patients by applying the provisional paediatric biopharmaceutical classification system." British Journal of Clinical Pharmacology 84(10): 2231-2241.
dc.identifier.issn0306-5251
dc.identifier.issn1365-2125
dc.identifier.urihttps://hdl.handle.net/2027.42/146268
dc.publisherWiley Periodicals, Inc.
dc.publisherWorld Health Organization
dc.subject.otherbiopharmaceutical optimization
dc.subject.otherBiopharmaceutics Classification System
dc.subject.otherneglected diseases
dc.subject.otherpaediatrics
dc.subject.othersecurity
dc.titleBiopharmaceutical optimization in neglected diseases for paediatric patients by applying the provisional paediatric biopharmaceutical classification system
dc.typeArticleen_US
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelPharmacy and Pharmacology
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/146268/1/bcp13650.pdf
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/146268/2/bcp13650_am.pdf
dc.identifier.doi10.1111/bcp.13650
dc.identifier.sourceBritish Journal of Clinical Pharmacology
dc.identifier.citedreferenceBayer Inc. Biltricide Product Monograph [online]. Bayer Inc. Available at http://omr.bayer.ca/omr/online/biltricideâ pmâ en.pdf (last accessed 16 June 2018).
dc.identifier.citedreferenceChemicalize by ChemAxon [online]. Chemicalize. Available at https://chemicalize.com/#/calculation (last accessed 16 June 2018).
dc.identifier.citedreferenceKasim NA, Whitehouse M, Ramachandran C, Bermejo M, Lennernäs H, Hussain AS, et al. Molecular properties of WHO essential drugs and provisional biopharmaceutical classification. Mol Pharm 2004; 1: 85 â 96.
dc.identifier.citedreferenceDahan A, Wolk O, Kim YH, Ramachandran C, Crippen GM, Takagi T, et al. Purely in silico BCS classification: science based quality standards for the world’s drugs. Mol Pharm 2013; 10: 4378 â 4390.
dc.identifier.citedreferenceLindenberg M, Kopp S, Dressman JB. Classification of orally administered drugs on the World Health Organization Model list of Essential Medicines according to the Biopharmaceutics Classification System. Eur J Pharm Biopharm 2004; 58: 265 â 278.
dc.identifier.citedreferenceGlaxoSmithKline. Zentel Product Monograph [online]. GlaxoSmithKline. Available at https://www.gsk.com.au/resources.ashx/prescriptionmedicinesproductschilddataproinfo/1252/FileName/214005870BB4EF194E1B5C2A6F986051/Zentel_PI_â _clean.pdf (last accessed 16 June 2018).
dc.identifier.citedreferenceLab. Elea. Abarax Product Monograph [online]. Lab. Elea. Available at http://www.elea.com/es/productos/1204/354/ABARAX.htm (last accessed 16 June 2018).
dc.identifier.citedreferenceMerck Sharp & Dohme Corp. Stromectol Product Monograph [online]. Merck Sharp & Dohme Corp. Available at https://www.merck.com/product/usa/pi_circulars/s/stromectol/stromectol_pi.pdf (last accessed 16 June 2018).
dc.identifier.citedreferenceANMAT BI. Lampit Product Monograph [online]. ANMAT. Available at http://www.anmat.gov.ar/boletin_anmat/enero_2016/Dispo_0469â 16.pdf (last accessed 16 June 2018).
dc.identifier.citedreferenceGlaxoSmithKline. Malarone Product Monograph [online]. GlaxoSmithKline. Available at http://ca.gsk.com/media/591413/malarone.pdf (last accessed 16 June 2018).
dc.identifier.citedreferenceFabiano V, Mameli C, Zuccotti GV. Paediatric pharmacology: remember the excipients. Pharmacol Res 2011; 63: 362 â 365.
dc.identifier.citedreferenceSalunke S, Giacoia G, Tuleu C. The STEP (Safety and Toxicity of Excipients for Paediatrics) database. Part 1 â a need assessment study. Int J Pharm 2012; 435: 101 â 111.
dc.identifier.citedreferenceSalunke S, Brandys B, Giacoia G, Tuleu C. The STEP (Safety and Toxicity of Excipients for Paediatrics) database. Part 2 â the pilot version. Int J Pharm 2013; 457: 310 â 322.
dc.identifier.citedreferenceTripathi A, Parmar D, Patel U, Patel G, Daslaniya D, Bhimani B. Taste masking: a novel approach for bitter and obnoxious drugs. JPSBR 2011; 1: 136 â 142.
dc.identifier.citedreferenceMaharaj AR, Edginton AN, Fotaki N. Assessment of ageâ related changes in pediatric gastrointestinal solubility. Pharm Res 2016; 33: 52 â 71.
dc.identifier.citedreferenceBatchelor H, Ernest T, Flanagan T, Klein S, Turner R, Fotaki N, et al. Towards the development of a paediatric biopharmaceutics classification system: Results of a survey of experts. Int J Pharm 2016; 511: 1151 â 1157.
dc.identifier.citedreferenceBatchelor H. European Paediatric Formulation Initiative (EUPFI). Paediatric biopharmaceutics classification system: current status and future decisions. Int J Pharm 2014; 469: 251 â 253.
dc.identifier.citedreferenceShawahna R. Pediatric Biopharmaceutical Classification System: using ageâ appropriate initial gastric volume. AAPS J 2016; 18: 728 â 736.
dc.identifier.citedreferenceGandhi SV, Rodriguez W, Khan M, Polli JE. Considerations for a pediatric Biopharmaceutics Classification System (BCS): application to five drugs. AAPS PharmSciTech 2014; 15: 601 â 611.
dc.identifier.citedreferenceCastro SG, Bruni SS, Lanusse CE, Allemandi DA, Palma SD. Improved albendazole dissolution rate in pluronic 188 solid dispersions. AAPS PharmSciTech 2010; 11: 1518 â 1525.
dc.identifier.citedreferencePubchem. BENZNIDAZOLE|C12H12N4O3 [online]. Available at: https://pubchem.ncbi.nlm.nih.gov/compound/benznidazole (last accessed 16 June 2018).
dc.identifier.citedreferenceMaximiano FP, Costa GHY, de Souza J, da Cunhaâ Filho MSS. Caracterização físicoâ química do fármaco antichagásico benznidazol. Quím Nova 2010; 33: 1714 â 1719.
dc.identifier.citedreferenceTakano R, Sugano K, Higashida A, Hayashi Y, Machida M, Aso Y, et al. Oral absorption of poorly waterâ soluble drugs: computer simulation of fraction absorbed in humans from a miniscale dissolution test. Pharm Res 2006; 23: 1144 â 1156.
dc.identifier.citedreferenceTrastullo R, Dolci LS, Passerini N, Albertini B. Development of flexible and dispersible oral formulations containing praziquantel for potential schistosomiasis treatment of preâ school age children. Int J Pharm 2015; 495: 536 â 550.
dc.identifier.citedreferenceDrugBank, editor. Proguanil. In: DrugBank [online]. 2016. Available at: https://www.drugbank.ca/drugs/DB01131 (last accessed 16 June 2018).
dc.identifier.citedreferenceWorld Health Organization. Neglected tropical diseases [online]. Available at http://www.who.int/neglected_diseases/diseases/en/ (last accessed 16 June 2018).
dc.identifier.citedreferenceUtzinger J, Becker SL, Knopp S, Blum J, Neumayr AL, Keiser J, et al. Neglected tropical diseases: diagnosis, clinical management, treatment and control. Swiss Med Wkly 2012; 142: w13727.
dc.identifier.citedreferenceSalunke S, Liu F, Batchelor H, Walsh J, Turner R, Ju TR, et al. European Paediatric Formulation Initiative (EuPFI) â formulating ideas for better medicines for children. AAPS PharmSciTech 2017; 18: 257 â 262.
dc.identifier.citedreferenceAli AA, Charoo NA, Abdallah DB. Pediatric drug development: formulation considerations. Drug Dev Ind Pharm 2014; 40: 1283 â 1299.
dc.identifier.citedreferenceAbdelâ Rahman SM, Amidon GL, Kaul A, Lukacova V, Vinks AA, Knipp GT, et al. Summary of the National Institute of Child Health and Human Development â Best Pharmaceuticals for Children Act pediatric formulation initiatives workshop â pediatric Biopharmaceutics Classification System Working Group. Clin Ther 2012; 34: S11 â S24.
dc.identifier.citedreferenceZajicek A, Fossler MJ, Barrett JS, Worthington JH, Ternik R, Charkoftaki G, et al. A report from the Pediatric Formulations Task Force: perspectives on the state of childâ friendly oral dosage forms. AAPS J 2013; 15: 1072 â 1081.
dc.identifier.citedreferenceAmidon GL, Lennernäs H, Shah VP, Crison JR. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res 1995; 12: 413 â 420.
dc.identifier.citedreferenceShah VP, Amidon GL. G.L. Amidon, H. Lennernas, V.P. Shah and J.R. Crison. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability, Pharm Res 12, 413â 420, 1995 â backstory of BCS. AAPS J 2014; 16: 894 â 899.
dc.identifier.citedreferenceDahan A, Miller JM, Amidon GL. Prediction of solubility and permeability class membership: provisional BCS classification of the world’s top oral drugs. AAPS J 2009; 11: 740 â 746.
dc.identifier.citedreferenceTeam â EuPFI [online]. Available at http://www.eupfi.org/team/ (last accessed 16 June 2018).
dc.identifier.citedreferenceGiacoia GP, Taylorâ Zapata P, Mattison D. Eunice Kennedy Shriver National Institute of Child Health and Human Development Pediatric Formulation Initiative: selected reports from working groups. Clin Ther 2008; 30: 2097 â 2101.
dc.identifier.citedreferenceHussaarts L, van der Weijde K, Dome P, Kouranyâ Lefoll E, Reinhardâ Rupp J, de Vrueh R, et al. Product development programs for neglected tropical diseases: a crucial role for expert meetings. PLoS Negl Trop Dis 2017; 11: e0005183.
dc.identifier.citedreferenceDrugs for Neglected Diseases initiative (DNDi) [online]. Available at https://www.dndi.org/aboutâ dndi/ (last accessed 16 June 2018).
dc.identifier.citedreferenceEMA, Guideline on Pharmaceutical Development of Medicines for Paediatric Use, Rev.1, EMA/CHMP/QWP/805880/2012, 2013 [online]. Available at http://www.ema.europa.eu/ema/index.jsp?curl=search.jsp&q=guideline+on+pharmaceutical+development+of+medicines+for+pediatric+use&btnG=Search&mid= (last accessed 16 June 2018).
dc.identifier.citedreferencePediatric Study Plans: Content of and Process for Submitting Initial Pediatric Study Plans and Amended Initial Pediatric Study Plans Guidance for Industry [online]. [cited 2016 Feb 21]. Available at https://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm360507.pdf (last accessed 16 June 2018).
dc.identifier.citedreferenceWorld Health Organization Model Lists of Essential Medicines [online]. Available at http://www.who.int/medicines/publications/essentialmedicines/en/ (last accessed 16 June 2018).
dc.identifier.citedreferenceBest Pharmaceuticals for Children Act (BPCA) Priority List of Needs in Pediatric Therapeutics, NIH â Feb 2017 [online]. Available at https://bpca.nichd.nih.gov/prioritization/status/Documents/2017_Priority_List.pdf (last accessed 16 June 2018).
dc.identifier.citedreferenceOh DM, Curl RL, Amidon GL. Estimating the fraction dose absorbed from suspensions of poorly soluble compounds in humans: a mathematical model. Pharm Res 1993; 10: 264 â 270.
dc.identifier.citedreferenceUS Department of Health and Human Services Food and Drug Administration. Guidance for Industry Bioavailability and Bioequivalence Studies for Orally Administered Drug Products â General Considerations. 2003.
dc.identifier.citedreferenceMosteller RD. Simplified calculation of bodyâ surface area. N Engl J Med 1987; 317: 1098.
dc.identifier.citedreferenceThe WHO Child Growth Standards [online]. Available at http://www.who.int/childgrowth/standards/en/ (last accessed 16 June 2018).
dc.identifier.citedreferenceStatureâ forâ age and Weightâ forâ age percentiles. 2 to 20 years: Boys. Centers for Disease Control and Prevention (CDC) [online]. 2000. Available at http://www.cdc.gov/growthcharts (last accessed 16 June 2018).
dc.identifier.citedreferenceWHO Model Prescribing Information: Drugs Used in Parasitic Diseases, 2nd edn. Geneva: World Health Organization, 1995.
dc.identifier.citedreferenceWorld Health Organization. WHO Model Formulary for Children. 2010.
dc.identifier.citedreferenceLeFever Kee J, Marshall SM, Forrester MC, Woods K. Clinical calculations: With applications to general and speciality areas, 8th edn. St. Louis, MO: Elsevier, 2016.
dc.identifier.citedreferenceThe International Pharmacopoeia Fifth Edition. WHO [online]. Available at http://apps.who.int/phint/en/p/docf/ (last accessed 16 June 2018).
dc.identifier.citedreferenceBudavari S. The Merck index: an encyclopedia of chemicals, drugs, and biologicals, 13th edn. Whitehouse Station, NJ: Merck, 2001.
dc.identifier.citedreferenceBatchelor HK, Fotaki N, Klein S. Paediatric oral biopharmaceutics: key considerations and current challenges. Adv Drug Deliv Rev 2014; 73: 102 â 126.
dc.identifier.citedreferenceNicolas Jâ M, Bouzom F, Hugues C, Ungell Aâ L. Oral drug absorption in pediatrics: the intestinal wall, its developmental changes and current tools for predictions. Biopharm Drug Dispos 2017; 38: 209 â 230.
dc.identifier.citedreferenceKearns GL, Abdelâ Rahman SM, Alander SW, Blowey DL, Leeder JS, Kauffman RE. Developmental pharmacology â drug disposition, action, and therapy in infants and children. N Engl J Med 2003; 349: 1157 â 1167.
dc.identifier.citedreferencevan den Anker JN, van Lingen RA, Koster M, Heykants J, Sauer PJ. Insufficient ketoconazole concentrations in preterm infants with fungal infections. Eur J Pediatr 1993; 152: 538.
dc.identifier.citedreferenceAlcorn J, McNamara PJ. Pharmacokinetics in the newborn. Adv Drug Deliv Rev 2003; 55: 667 â 686.
dc.identifier.citedreferenceSugano K, Kansy M, Artursson P, Avdeef A, Bendels S, Di L, et al. Coexistence of passive and carrierâ mediated processes in drug transport. Nat Rev Drug Discov 2010; 9: 597 â 614.
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
bcp13650.pdf
Size:
292.2KB
Format:
PDF
View/Open
Name:
bcp13650_am.pdf
Size:
497.4KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.